Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

125.02 -0.18 (-0.14%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
67 68 Next >
News headline image
Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
From Gilead Sciences, Inc.
Via Business Wire
News headline image
3 Spectacular High-Yield Dividend Stocks to Buy in November ↗
High yields aren't a warning indicator with these three stocks. 
Via The Motley Fool
News headline image
Gilead Sciences to Present at Upcoming Investor Engagements
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks ↗
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and... 
Via Benzinga
News headline image
3 Healthcare Stocks For Long-Term Growth And Dividends ↗
Healthcare stocks will profit from the U.S. aging population and pay rising dividends over time. 
Via Talk Markets
News headline image
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review ↗
A Fed rate cut and a slew of big earnings reports filled out a busy week. 
Via Investor's Business Daily
Topics Economy Government
News headline image
Smaller Cap Biotechs Are In Season: How Are We Doing? ↗
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
News headline image
HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook ↗
Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst upgrades boosting investor confidence. 
Via Benzinga
Topics Earnings
News headline image
Gilead Sciences's Earnings: A Preview ↗
 
Via Benzinga
News headline image
AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies
Via ACCESSWIRE
News headline image
Peering Into Gilead Sciences's Recent Short Interest ↗
 
Via Benzinga
News headline image
Nasdaq 100 Extends Record Levels Ahead Of Fed Meeting, Tesla Hits 26-Month Highs, Small Caps Stall: What's Driving Markets Thursday? ↗
After Wednesday’s “everything rally” spurred by the election results, investors took a less euphoric approach on Thursday ahead of the Federal Open Market Committee (FOMC) meeting. The Fed is widely... 
Via Benzinga
Topics Economy
News headline image
Gilead’s Stock Surge: What’s Fueling the Momentum?
Gilead Sciences' financial performance, innovative therapies, and strategic investments position the company for continued growth. 
Via MarketBeat
News headline image
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Evaluating Gilead Sciences: Insights From 15 Financial Analysts ↗
 
Via Benzinga
News headline image
Gilead Sciences (GILD) Q3 2024 Earnings Call Transcript ↗
GILD earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Gilead Sciences Announces Third Quarter 2024 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Easily Beats Third-Quarter Views Driven By Solid Biktarvy Sales ↗
The company also raised its earnings and sales guidance for the year. 
Via Investor's Business Daily
News headline image
Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required ↗
A bit of earnings and election jitters roiled the market last week reordering the leaderboard in biopharma stocks. 
Via Talk Markets
News headline image
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy ↗
Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities. 
Via Benzinga
News headline image
3 Absurdly Cheap Stocks That Pay High Dividends ↗
These stocks are trading at less than 15 times their expected future profits. 
Via The Motley Fool
News headline image
Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise ↗
There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle. 
Via Talk Markets
News headline image
Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks ↗
Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable success... 
Via Benzinga
News headline image
Robinhood To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
This JD.com Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗
 
Via Benzinga
News headline image
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
From Gilead Sciences, Inc.
Via Business Wire
News headline image
After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment ↗
Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory results from the TROPiCS-04 study. However, the decision does not impact... 
Via Benzinga
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.